Business Context and Reporting Period
This Form 8-K was filed by SANUWAVE Health, Inc. on September 25, 2023. The filing serves as a Regulation FD disclosure to provide an investor presentation regarding a proposed merger with SEP Acquisition Corp. (SEPA). The transaction is governed by a Merger Agreement dated August 23, 2023.
Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity for SANUWAVE Health, Inc. or the combined entity. The document focuses on the procedural aspects of the merger and the attached investor presentation rather than reporting period financial results.
Material Changes
No material changes to historical financial performance are reported in this document. The primary material event is the progression of the merger transaction with SEPA, for which an investor presentation has been prepared and attached as Exhibit 99.1.
Guidance, Outlook, and Risks
Outlook and Conditions: The filing outlines significant conditions precedent for the merger to close, including:
- Approval by holders of 80% of SANUWAVE's outstanding convertible promissory notes and warrants.
- SEPA must have at least $12.0 million at closing, derived from non-redeemed Class A common stock proceeds and a private placement.
- Approval from stockholders of both SANUWAVE and SEPA.
- Obtaining necessary regulatory approvals and maintaining Nasdaq listing status for SEPA post-transaction.
Risks and Contingencies: The document includes extensive forward-looking statement disclaimers. Key risks identified include:
- Failure to satisfy closing conditions or obtain stockholder approvals.
- Termination of the Merger Agreement due to unforeseen events.
- Delays in regulatory approvals.
- Costs associated with the transaction.
- General economic, business, and competitive factors.
Management Commentary: Management directs investors to read the upcoming Form S-4 registration statement and proxy statements for detailed information on the transactions, noting that this 8-K does not constitute a solicitation of proxies or an offer to sell securities.
Key Facts for Investor Verification
- Verify the status of the 80% approval requirement for convertible note and warrant holders.
- Confirm SEPA's ability to secure the required $12.0 million in closing proceeds.
- Monitor the filing of the Form S-4 and proxy statements for detailed risk factors and transaction terms.
- Check for updates on Nasdaq listing requirements for the combined entity.
- Review the attached Investor Presentation (Exhibit 99.1) for specific financial projections not included in this text.